CoreBone

Company Overview

Snapshot

Founded in December 2011 by Ohad Schwartz and Prof. Itzhak Binderman, CoreBone operates with 1–10 employees. The company has raised $6.32 million across three funding rounds from five investors. In October 2021, CoreBone secured a significant investment to commercialize its bioactive bone graft material and expand its activities in China.

Business overview

CoreBone develops and commercializes bioactive coral-based bone grafts for dental and orthopedic applications. Its core technology involves culturing coral in a monitored system to enrich the graft with silicium and strontium, providing biomimetic bone-like qualities such as strength, porosity, resorption, and bioactivity, without relying on human or animal bone sources. The company's products, including CoreBon1000, CoreBlock, CoreBlock Cone, CoreBone 500, and CoreBone 2000, are CE and ISO 13485 certified and serve the health tech and life sciences sectors, specifically in biomaterials and tissue engineering, targeting healthcare providers and distributors in markets such as China and Europe.

Strategic signal

In October 2021, CoreBone raised a $3.7 million investment, led by Guangzhou Sino-Israel Biotech Investment Fund (GIBF), to commercialize its bioactive bone graft material and expand into the Chinese market. This funding signifies strong investor confidence in CoreBone's proprietary coral-based technology and its potential to address significant needs in dental and orthopedic treatments, marking a critical step towards broader market penetration and scaling its operations.

Company Intelligence Q&A

What is CoreBone's primary product offering?

CoreBone develops bioactive coral-based bone grafts for dental and orthopedic indications, offering products like CoreBon1000, CoreBlock, CoreBlock Cone, CoreBone 500, and CoreBone 2000.

When was CoreBone founded and by whom?

CoreBone was founded in December 2011 by Ohad Schwartz and Prof. Itzhak Binderman.

What was a key funding event for CoreBone in 2021?

In October 2021, CoreBone raised a $3.7 million investment, led by Guangzhou Sino-Israel Biotech Investment Fund (GIBF), to commercialize its bioactive bone graft material and expand into China.

What certifications do CoreBone's products hold?

CoreBone's products are CE and ISO 13485 certified, indicating compliance with European health, safety, and environmental protection standards and quality management systems for medical devices.

Which investor participated in CoreBone's Seed round in January 2013?

In January 2013, The Trendlines Group participated in CoreBone's Seed funding round.